Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details
Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details
Retail pharmacy giant Walgreens Boots Alliance Inc (NASDAQ:WBA) is bolstering its specialty pharmacy services, aiming to enhance patient outcomes and value for stakeholders.
零售药房巨头Walgreens Boots Alliance Inc（纳斯达克股票代码：WBA）正在加强其专业药房服务，旨在提高患者疗效和利益相关者的价值。
The company unveiled Walgreens Specialty Pharmacy, an encompassing initiative to cater to patients with complex, chronic conditions while fostering profitable partnerships.
该公司推出了Walgreens Specialty Pharmacy，这是一项全面的计划，旨在满足复杂慢性病患者的需求，同时促进盈利的合作伙伴关系。
Read Next: Walgreens Challenges Nearly $1B Arbitration Award Over Alleged Breach of COVID-19 Test Business Contract
阅读下一页：沃尔格林因涉嫌违反 COVID-19 测试商业合同对近 10 亿美元的仲裁裁决提出质疑
Walgreens Specialty Pharmacy introduces a comprehensive suite of services, including gene and cell therapy solutions, marking a significant advancement in the company's healthcare offerings.
Walgreens Specialty Pharmacy推出了一整套服务，包括基因和细胞疗法解决方案，这标志着该公司医疗保健产品的重大进步。
Anchored by an 18,000-square-foot Innovation Center in Pittsburgh, Pennsylvania, the initiative focuses on managing therapy complexities and ensuring patient success.
该计划由宾夕法尼亚州匹兹堡占地18,000平方英尺的创新中心主持，侧重于管理治疗的复杂性并确保患者成功。
Under the expanded business, Walgreens will operate four central specialty pharmacies, each with national accreditations and expertise in dispensing intricate medications.
在扩大的业务下，沃尔格林将经营四家中央专业药房，每家药房均获得国家认证和配发复杂药物方面的专业知识。
Additionally, the company's expansive network comprises nearly 300 community-based specialty pharmacies, strategically positioned for swift medication access and tailored patient services.
此外，该公司庞大的网络包括近300家以社区为基础的专业药房，这些药房处于战略地位，可快速获得药物和提供量身定制的患者服务。
Also Read: Walgreens Boots Alliance Cuts Higher End Of 2024 Profit Outlook, Takes $5.8B Impairment Charge Related To VillageMD Business
另请阅读: Walgreens Boots Alliance下调了2024年底的利润展望，收取了与VillageMD业务相关的58亿美元减值费用
With over 1,500 specialty-trained pharmacists and 5,000 patient advocacy support members, Walgreens Specialty Pharmacy is primed to address the burgeoning demand for specialized care.
沃尔格林专业药房拥有1,500多名受过专业培训的药剂师和5,000名患者权益支持成员，已准备好满足对专业护理不断增长的需求。
Specialty medications constitute a significant portion of the U.S. prescription drug market, driving the need for tailored solutions.
特种药物占美国处方药市场的很大一部分，推动了对量身定制解决方案的需求。
Walgreens Specialty Pharmacy aims to meet this demand by streamlining care coordination across stakeholders, thereby enhancing patient access and driving cost efficiencies.
Walgreens Specialty Pharmacy旨在通过简化利益相关者之间的护理协调来满足这一需求，从而增加患者就诊机会并提高成本效率。
Effective August 1, 2024, AllianceRx Walgreens Pharmacy will transition to Walgreens Specialty Pharmacy, offering enhanced resources and clinical support to patients.
自2024年8月1日起，AlliancerX Walgreens Pharmacy将过渡到沃尔格林专业药房，为患者提供更多的资源和临床支持。
Walgreens stock lost over 48% in the last 12 months. Investors can gain exposure to the stock via Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:PEY) and Invesco Dow Jones Industrial Average Dividend ETF (NYSE:DJD).
在过去的12个月中，沃尔格林的股票下跌了48％以上。投资者可以通过景顺高收益股票分红ETF（纳斯达克股票代码：PEY）和景顺道琼斯工业平均股息ETF（纽约证券交易所代码：DJD）获得股票敞口。
Price Action: WBA shares are trading higher by 0.79% at $17.94 in premarket at last check Thursday.
价格走势：在周四的最后一次盘前检查中，WBA股价上涨0.79％，至17.94美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明: 该内容部分是在 AI 工具的帮助下制作的，由 Benzinga 编辑审阅和发布。
Photo via Wikimedia Commons
照片来自维基共享资源
译文内容由第三方软件翻译。